This is, for example, reflected in the fact that the two leading diabetes societies, the ADA and the EASD, founded a “Precision Medicine in Diabetes Initiative” in 2018, issued a common consensus report [1], two updates [2, 3], and commissioned a number of systematic reviews on the topic, e.g. on treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors [4]. This evidence concerns the gene GLP1R and diabetes mellitus.